| Autor: |
De Santis GC, Oliveira LC, Garibaldi PMM, Almado CEL, Croda J, Arcanjo GGA, Oliveira ÉAF, Tonacio AC, Langhi DM Jr, Bordin JO, Gilio RN, Palma LC, Santos EV, Haddad SK, Prado BPA Jr, Pontelli MC, Gomes R, Miranda CH, Auxiliadora Martins M, Covas DT, Arruda E, Fonseca BAL, Calado RT |
| Jazyk: |
angličtina |
| Zdroj: |
Emerging infectious diseases [Emerg Infect Dis] 2022 Mar; Vol. 28 (3), pp. 548-555. Date of Electronic Publication: 2022 Jan 26. |
| DOI: |
10.3201/eid2803.212299 |
| Abstrakt: |
To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
